0000950170-22-010067.txt : 20220516 0000950170-22-010067.hdr.sgml : 20220516 20220516160342 ACCESSION NUMBER: 0000950170-22-010067 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220516 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220516 DATE AS OF CHANGE: 20220516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ginkgo Bioworks Holdings, Inc. CENTRAL INDEX KEY: 0001830214 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 872652913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40097 FILM NUMBER: 22928655 BUSINESS ADDRESS: STREET 1: 27 DRYDOCK AVENUE STREET 2: 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: (877) 442-5362 MAIL ADDRESS: STREET 1: 27 DRYDOCK AVENUE STREET 2: 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Soaring Eagle Acquisition Corp. DATE OF NAME CHANGE: 20210210 FORMER COMPANY: FORMER CONFORMED NAME: Spinning Eagle Acquisition Corp. DATE OF NAME CHANGE: 20201027 8-K 1 dna-20220516.htm 8-K 8-K
0001830214false0001830214us-gaap:CommonClassAMember2022-05-162022-05-160001830214us-gaap:WarrantMember2022-05-162022-05-1600018302142022-05-162022-05-16

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 16, 2022

 

GINKGO BIOWORKS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-40097

 

87-2652913

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

27 Drydock Avenue

8th Floor

Boston, MA 02210

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (877) 422-5362

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Class A common stock, par value $0.0001 per share

 

DNA

 

NYSE

Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share

 

DNA.WS

 

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

On May 16, 2022, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2022. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
 


 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
Number

 

Description

 

 

 

99.1

Press Release, issued by Ginkgo Bioworks Holdings, Inc. on May 16, 2022

 

 

 

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

GINKGO BIOWORKS HOLDINGS, INC.

 

 

 

 

Date: May 16, 2022

 

By:

/s/ Mark Dmytruk

 

 

Name:

Mark Dmytruk

 

 

Title:

Chief Financial Officer

 

 

 

 EX-99.1 2 dna-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

 

img197909486_0.jpg 

 

Ginkgo Bioworks Reports First Quarter 2022 Financial Results

 

$168 million of Total revenue in Q1 2022, representing an increase of 282% over Q1 2021

11 new Cell Programs added in Q1 2022, representing 175% growth over Q1 2021

Increasing full year guidance for Total revenue from $325 – $340 million to $375– $390 million, reiterating Foundry revenue guidance and increasing Biosecurity revenue guidance

Recently announced plans to expand platform capabilities in agricultural biologicals through a series of M&A transactions and flagship collaboration with Bayer

$1.5 billion cash balance provides meaningful multi-year runway as we drive towards profitability

 

BOSTON, MA -- May 16, 2022 -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), the leading horizontal platform for cell programming, today announced its results for the first quarter ended March 31, 2022. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

 

“We sometimes remark that the pace of change never seems to slow at Ginkgo, and the beginning of 2022 has been no exception,” said Jason Kelly, co-founder and CEO of Ginkgo. “We added 11 new programs in our cell programming business in the first quarter of 2022, including in many novel areas of work, and realized record revenues in our biosecurity business. We believe we are well positioned for this market downturn and expect to continue to invest in platform growth, both organically and through M&A, while ensuring we maintain a healthy balance sheet. We are particularly excited about our planned transactions with Bayer, in which they will be establishing a flagship partnership with Ginkgo in the field of agricultural biologicals and transferring their physical platform and team to Ginkgo to extend our platform capabilities in this field. We expect to see strategic moves like this in other industries in the coming years.”

 

Recent Business Highlights & Strategic Positioning

•
Added 11 new Cell Programs to the Foundry platform in Q1 2022, representing 175% growth over the prior year period
•
Concentric, Ginkgo’s biosecurity and public health offering, grew rapidly in Q1, reaching $147 million in revenue
o
Concentric has continued to empower communities with COVID-19 monitoring programs across the United States while piloting new modalities and offerings, including passive monitoring of wastewater and air
o
Since inception, Concentric has tested more than 9,000,000 samples for SARS-CoV-2, including an average of over 260,000 individual samples per week over the past three months, and has sequenced over 31,000 viral samples
o
Concentric is well-positioned to play a role in the response to longer-term needs, including endemic COVID-19 and broader infectious disease preparedness and public health response
•
Closed acquisition of FGen AG, a Swiss company specializing in ultra-high-throughput (uHT) screening for strain development and optimization
o
FGen's technology is expected to significantly enhance Ginkgo's cell screening capabilities and enable Ginkgo to explore wider expanses of genetic opportunity space
•
Announced plan to expand platform capabilities in agricultural biologics and launch flagship partnership with Bayer
o
Ginkgo plans to acquire Bayer's West Sacramento agricultural biologicals site and team and gain access to Bayer's large agricultural strain collection
o
Bayer is expected to be a flagship customer of Ginkgo’s agricultural biologicals offering, upon entering into a significant new multi-year, multi-product collaboration, building on the work done by Joyn Bio, the joint venture between Ginkgo Bioworks and Leaps by Bayer, which is expected to be integrated into Ginkgo

 

First Quarter 2022 Financial Highlights

•
First quarter 2022 Total revenue of $168 million, up from $44 million in the comparable prior year period, an increase of 282%
•
First quarter 2022 Foundry revenue of $21 million, down from $23 million in the comparable prior year period, a decrease of 5%. First quarter 2022 Foundry revenue did not include material downstream value share payments and included a
higher mix of early-stage programs that have not yet ramped or achieved significant technical milestones which drive revenue recognition
•
First quarter 2022 Biosecurity revenue of $147 million with gross profit margin of 42%
•
First quarter 2022 Loss from operations of $(675) million (inclusive of stock-based compensation expense of $659 million), compared to Loss from operations of $(57) million in the comparable prior year period. The stock-based compensation expense primarily relates to the continued GAAP accounting for the modification of restricted stock units issued prior to becoming a public company, as disclosed in our Form 10-K filed with the SEC on March 29, 2022
•
First quarter 2022 Adjusted EBITDA of $(2) million, improved from $(51) million in the comparable prior year period
•
Cash and cash equivalents balance as of the end of the first quarter of $1.5 billion puts Ginkgo in a strong financial position to pursue its strategic objectives

 

Full Year 2022 Guidance

•
Ginkgo continues to expect to add 60 new Cell Programs to the Foundry platform in 2022
•
Ginkgo increased its expectation for Total revenue from $325 – $340 million to $375 – $390 million in 2022
o
Ginkgo continues to expect Foundry revenue of $165 – $180 million in 2022
o
While Biosecurity remains an uncertain business, based on strong year-to-date performance Ginkgo now expects Biosecurity revenue in 2022 of at least $210 million

 

Conference Call Details

Ginkgo will host a videoconference today, Monday, May 16, 2022, beginning at 4:30 p.m. ET. The presentation will include an overview of the first quarter financial performance, recent business updates, a discussion on Ginkgo’s outlook, as well as a moderated question and answer session.

 

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on Twitter (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.

 

A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.

 

Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/

 

Audio-Only Dial Ins:
+1 646 876 9923 (New York)

+1 301 715 8592 (Washington DC)

+1 312 626 6799 (Chicago)

+1 669 900 6833 (San Jose)

+1 253 215 8782 (Tacoma)

+1 346 248 7799 (Houston)

+1 408 638 0968 (San Jose)

 

Webinar ID: 928 8373 1262

 

If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our web site at https://investors.ginkgobioworks.com/events/ for updated dial-in information.

 

About Ginkgo Bioworks

Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization, and therapeutics discovery. For more information, visit www.ginkgobioworks.com.

 

Forward-Looking Statements of Ginkgo Bioworks

This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, current expectations, operations and anticipated results of operations, both business and financial, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the

words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the effect of Ginkgo's business combination with Soaring Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's business relationships, performance, and business generally, (ii) risks that the business combination disrupts current plans of Ginkgo and potential difficulties in Ginkgo's employee retention, (iii) the outcome of any legal proceedings that may be instituted against Ginkgo related to its business combination with Soaring Eagle, (iv) volatility in the price of Ginkgo's securities now that it is a public company due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo's business, changes in the combined capital structure and expectations associated with increases in the number of shares available for sale, (v) the ability to implement business plans, forecasts, and other expectations after the completion of the business combination, and ability to identify and realize additional opportunities, (vi) the risk of downturns in demand for products using synthetic biology, (vii) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19 testing business, and (viii) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on March 29, 2022, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

 

Use of Non-GAAP Financial Measures

Certain of the financial measures included in this release, including Adjusted EBITDA, have not been prepared in accordance with generally accepted accounting principles (“GAAP”), and constitute “non-GAAP financial measures” as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo’s financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo’s most comparable GAAP financial measures.

 

 

Ginkgo Bioworks Contacts:

 

INVESTOR CONTACT:

investors@ginkgobioworks.com

 

MEDIA CONTACT:

press@ginkgobioworks.com

 


 

 

 

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except per share data, unaudited)

 

 

 

 

 

 

 

As of March 31,

 

As of December 31,

 

 

2022

 

2021

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

 $ 1,492,971

 

 $ 1,550,004

Accounts receivable, net

 

167,256

 

131,544

Accounts receivable - related parties

 

3,814

 

4,598

Inventory, net

 

8,697

 

3,362

Prepaid expenses and other current assets

 

33,094

 

33,537

Total current assets

 

1,705,832

 

1,723,045

Property and equipment, net

 

149,171

 

145,770

Investments

 

103,031

 

102,037

Equity method investments

 

8,207

 

13,194

Intangible assets, net

 

20,829

 

21,642

Goodwill

 

21,040

 

21,312

Other non-current assets

 

49,616

 

43,990

Total assets

 

 $ 2,057,726

 

 $ 2,070,990

Liabilities and Stockholders’ Equity

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

 

 $35,257

 

 $8,189

Deferred revenue

 

35,232

 

33,240

Accrued expenses and other current liabilities

 

88,758

 

93,332

Total current liabilities

 

159,247

 

134,761

Non-current liabilities:

 

 

 

 

Deferred rent, net of current portion

 

19,262

 

18,746

Deferred revenue, net of current portion

 

170,176

 

155,991

Lease financing obligation

 

27,309

 

22,283

Warrant liabilities

 

50,803

 

135,838

Other non-current liabilities

 

16,881

 

35,992

Total liabilities

 

443,678

 

503,611

Commitments and contingencies

 

 

 

 

Stockholders’ equity:

 

 

 

 

Preferred stock, $0.0001 par value

 

—

 

—

Common stock, $0.0001 par value

 

162

 

161

Additional paid-in capital

 

4,471,418

 

3,804,844

Accumulated deficit

 

(2,888,430)

 

(2,297,925)

Accumulated other comprehensive loss

 

 (2,355)

 

 (1,715)

Total Ginkgo Bioworks Holdings, Inc. stockholders’ equity

 

1,580,795

 

1,505,365

Non-controlling interest

 

 33,253

 

 62,014

Total stockholders’ equity

 

1,614,048

 

1,567,379

Total liabilities and stockholders’ equity

 

 $ 2,057,726

 

 $ 2,070,990

 


 

 

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data, unaudited)

 

 

 

 

 

 

 

Three Months Ended March 31,

 

 

2022

 

2021

Foundry revenue

 

 $ 21,488

 

 $ 22,504

Biosecurity revenue:

 

 

 

 

Product

 

13,947

 

5,775

Service

 

132,970

 

15,818

Total revenue

 

168,405

 

44,097

Costs and operating expenses:

 

 

 

 

Cost of Biosecurity product revenue

 

8,095

 

9,935

Cost of Biosecurity service revenue

 

77,337

 

13,765

Research and development

 

322,720

 

59,585

General and administrative

 

434,768

 

17,927

Total operating expenses

 

842,920

 

101,212

Loss from operations

 

(674,515)

 

(57,115)

Other income (expense):

 

 

 

 

Interest expense, net

 

(397)

 

(475)

Loss on equity method investments

 

(20,887)

 

(28,624)

Gain on investments

 

450

 

12,622

Change in fair value of warrant liabilities

 

85,035

 

—

Gain on deconsolidation of subsidiary

 

15,900

 

—

Other income (expense), net

 

1,637

 

(1,345)

Total other income (expense), net

 

81,738

 

(17,822)

Loss before income taxes

 

(592,777)

 

(74,937)

Income tax benefit

 

(184)

 

(159)

Net loss

 

(592,593)

 

(74,778)

Net loss attributable to non-controlling interest

 

(2,088)

 

(1,209)

Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders

 

 $ (590,505)

 

 $ (73,569)

Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders, basic and diluted

 

  $ (0.37)

 

 $ (0.06)

Weighted average common shares outstanding, basic and diluted

 

1,607,499,887

 

1,290,282,994

Comprehensive loss:

 

 

 

 

Net loss

 

 $ (592,593)

 

 $ (74,778)

Other comprehensive loss:

 

 

 

 

Foreign currency translation adjustment

 

(640)

 

—

Total other comprehensive loss

 

(640)

 

—

Comprehensive loss

 

 $ (593,233)

 

 $ (74,778)

 


 

 

Ginkgo Bioworks Holdings, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands, unaudited)

 

 

 

 

 

 

 

Three Months Ended March 31,

 

 

2022

 

2021

Cash flows from operating activities:

 

 

 

 

Net loss

 

 $ (592,593)

 

 $ (74,778)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

Depreciation and amortization

 

 9,488

 

 5,629

Stock-based compensation

 

 652,821

 

118

Loss on equity method investments

 

 20,887

 

 28,624

Gain on investments

 

(450)

 

 (12,622)

Change in fair value of loans receivable

 

(584)

 

 1,825

Change in fair value of warrant liabilities

 

(85,035)

 

—

Change in fair value of contingent consideration liability

 

1,513

 

—

Gain on deconsolidation of subsidiary

 

(15,900)

 

—

Other non-cash activity

 

104

 

—

Changes in operating assets and liabilities:

 

 

 

 

Accounts receivable

 

 (34,928)

 

 (9,541)

Prepaid expenses and other current assets

 

700

 

 1,633

Inventory

 

 (5,335)

 

(681)

Other non-current assets

 

 2,212

 

(678)

Accounts payable

 

 26,250

 

516

Accrued expenses and other current liabilities

 

 9,973

 

 16,807

Deferred revenue, current and non-current

 

 11,444

 

 (5,512)

Deferred rent, non-current

 

516

 

688

Other non-current liabilities

 

 (20,981)

 

(159)

Net cash used in operating activities

 

 (19,898)

 

 (48,131)

Cash flows from investing activities:

 

 

 

 

Purchases of property and equipment

 

(3,580)

 

(21,935)

Prepayment for marketable equity securities

 

(3,691)

 

—

Deconsolidation of subsidiary - cash

 

(28,772)

 

—

Prepayment for business acquisition

 

—

 

(1,210)

Other

 

58

 

99

Net cash used in investing activities

 

 (35,985)

 

 (23,046)

Cash flows from financing activities:

 

 

 

 

Proceeds from exercise of stock options

 

75

 

27

Taxes paid related to net share settlement of equity awards

 

(981)

 

—

Principal payments on capital leases and lease financing obligation

 

(286)

 

(285)

Payment of deferred offering costs

 

—

 

(175)

Net cash used in financing activities

 

(1,192)

 

(433)

Effect of foreign exchange rates on cash and cash equivalents

 

(8)

 

—

Net decrease in cash, cash equivalents and restricted cash

 

(57,083)

 

(71,610)

 

 

 

 

 

Cash and cash equivalents, beginning of period

 

1,550,004

 

380,801

Restricted cash, beginning of period

 

42,924

 

5,076

Cash, cash equivalents and restricted cash, beginning of period

 

1,592,928

 

385,877

 

 

 

 

 

Cash and cash equivalents, end of period

 

1,492,971

 

308,128

Restricted cash, end of period

 

42,874

 

6,139

Cash, cash equivalents and restricted cash, end of period

 

 $ 1,535,845

 

 $ 314,267

 

Ginkgo Bioworks Holdings, Inc.

 

Selected Non-GAAP Financial Measures

 

(in thousands, unaudited)

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

2021

 

Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders

 

 $ (590,505)

 

 $ (73,569)

 

Interest expense, net

 

397

 

475

 

Income tax benefit

 

(184)

 

(159)

 

Depreciation and amortization

 

 9,488

 

5,629

 

EBITDA

 

 (580,804)

 

(67,624)

 

Stock-based compensation (1)

 

 659,035

 

118

 

Loss on equity method investments (2)

 

 20,264

 

27,415

 

Gain on investments (3)

 

(450)

 

(12,622)

 

Change in fair value of warrant liabilities

 

 (85,035)

 

—

 

Gain on deconsolidation of subsidiary

 

 (15,900)

 

—

 

Other (4)

 

939

 

1,575

 

Adjusted EBITDA

 

 $ (1,951)

 

 $ (51,138)

 

 
1.
For the three months ended March 31, 2022, includes $6.2 million in employer payroll taxes.

(2) For the three months ended March 31, 2022 and 2021, represents losses on equity method investments under the hypothetical liquidation at book value method of $20.9 million and $28.6 million, respectively, net of losses attributable to non-controlling interests.

(3) Includes gain on the change in fair value of our common stock investments in Synlogic and Cronos and warrants to purchase Synlogic common stock, which are all carried at fair value.

(4) For the three months ended March 31, 2022, includes a $0.6 million gain on the change in fair value of the Access Bio Convertible Notes offset by $1.5 million loss on the change in fair value of contingent consideration liability related to a business acquisition. For the three months ended March 31, 2021, includes $2.1 million loss on the change in fair value of the Access Bio Convertible Notes offset by a $0.5 million gain related to a settlement payment from Amyris.

 


 

 

Ginkgo Bioworks Holdings, Inc.

Segment Information

(in thousands, unaudited)

 

 

 

 

 

Three Months Ended March 31,

 

2022

 

2021

Revenue:

 

 

 

Foundry

 $ 21,488

 

 $ 22,504

Biosecurity

 146,917

 

 21,593

Total revenue

 168,405

 

 44,097

Segment cost of revenue:

 

 

 

Biosecurity

 85,432

 

 23,700

Segment research and development expense:

 

 

 

Foundry

 47,289

 

 30,894

Biosecurity

517

 

 23,403

Total segment research and development expense

 47,806

 

 54,297

Segment general and administrative expense:

 

 

 

Foundry

 26,693

 

 13,155

Biosecurity

 13,235

 

 4,535

Total segment general and administrative expense

 39,928

 

 17,690

Segment operating income (loss):

 

 

 

Foundry

 (52,494)

 

 (21,545)

Biosecurity

 47,733

 

 (30,045)

Total segment operating income (loss)

 (4,761)

 

 (51,590)

Operating expenses not allocated to segments:

 

 

 

Stock-based compensation (1)

 659,035

 

118

Depreciation and amortization

 9,206

 

 5,407

Change in fair value of contingent consideration liability

 1,513

 

—

Loss from operations

 $ (674,515)

 

 $ (57,115)

 

 

 

 

(1) For the three months ended March 31, 2022, includes $6.2 million in employer payroll taxes.

 

 

 GRAPHIC 3 img197909486_0.jpg GRAPHIC begin 644 img197909486_0.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W\G R:X.Z M^+&@VFNO8$2R6R9#7D?S+N] .I'O_3FM'XCI>OX(OFLKK[.4 :7G&^/H5SVS MD?7&.]?.51*5CSL9BITI*,3OOB%X]@\4+;V>GQ31VL#ER\AP9#T' Z <_GVK MB["_FT_4+>\B8^9!(LB\D9(.:] \&_"U==TNVU;4+\QV\Q)6"%AKJ7^#6@$3;+N_4L/W>74A/_'>:FS>IRO#XBL_:OJ(/C'H9TPS_ &6Z%V.! M;$#D_P"_TQ^&?:NN\-^);#Q1I:WMD^".)86/S1-Z'^A[UX'XD\$:UX:DD:YM MFDLU;"W40RA';/\ =^AK2^%:7LGC6%;2Z\E%C9YU)XD08RN._)'TZ]J:D[V9 MK2Q=955"HOZ[GT%2$A022 !R2>U+7#_%?4)['P6R0,R_:IU@=E_ND$D?CMQ^ M-6W8].K/V<'-]"S>_$WPM97)@-\TS*<,T,991^/0_AFN@TK6M.UNR^V:==)< M0]RO53Z$'D'ZURT1V4L2<]N#^E)X)U;PO>3 MZE;^']-FLY2OFS^9&%SSP!\QP!GIP!23[F$*LU-1FUKTZF_IOBK2-6TJ[U.S MN&>UM-QF*ET+Q)I7B."6;2[H3+$VUP5*E3VX/./?V->;_#[_ M ))GXH^D_P#Z)%<[X=74?">FZ?XOLB\UG+(T%[#V W8'Y]CV(]\4N8Q6+FE% MM:-79[7)XATV+Q!%H3SL-0E3S$CV'!&">N,=%-)!XBTRY\03Z'%.QU"!-\D> MQ@ .#UQC^(5P0O[;5/C+HE]:2"2WGL2Z,/39)P?0]L5A:_XAF\-?$_Q!>6T/ MF7+VXBB]$)2,[B.^ II\Q4L4XKF>W-;Y6/5I_%.DV^NQZ(;AI-0?'[F*-GQG MU(&!QSSVYIFN^+]$\.,L>HWH29AD0HI=\>N!T_&L/X=Z-96FAG7%N1?ZA?*9 M)[GJ0>I09Y'/7U/X5@_#/3[779=6\2ZK$EU>FX*J)1N"<;B0#]0!Z8XHNRO; M5&HI6O+\%^IVFA^.- \07'V:RO,7!Y$,JE&;Z9X/X5IZMK6G:%9_:M2NDMXL MX!;DL?0 "HUG8M]FF:!&/7: "/RW8_"G=WLS6$YQJBBBF= M 4444 >'?$7QY>:C/?>'H[=(+6"Y*.X8EI-AX]@,C/Y4WX3>&[?5]6NKZ^M8 MY[6U0*JR@%3(QXX/7 !_,5C>/=!U33_$>I7]U9R):7%W(T4V,JP))'([X[5U MWP4GMUDU: SD7#B-EB)X*C=D@?B/S%9+66IXD+SQ2]I_78])L-'&DWK_ -GL MD6GRY9[3'RQO_>C] >Z].XQSG5HI"RA@I8 GH">M:GM)**LCF_&^O:9HWAR\ M2_='DN(7CBMSRTA(QT].>37S[HFLW.@:S;ZG:;?-A;(5NC C!!]B":O^-I-0 MD\8:E_:6_P ]9F50W0)GY<>V,8K$M[>:[N([>WB>6:1@J(@R6)[ 5E)W9X.) MQ$JE2ZTML?2/@OQ,_BO03J$EL+=UE:)E5L@X .1^=7?$F@V_B30[C3;AB@D M*2 9*,.A_P ]LUA?#+1[_1/"C6VHV[03/BG5[:G$6$GQ#\-6BZ6FE6NJ00C9!<>8 M.%'0'Y@<#W ^M:?@OPOJ^G:AJ>M:U)"+W4 (+6)IX)3&%0MM/S.$(/7D$G\J5D9 M1A3B[N3T[_\ #'->#O"^L:5X&UW3;RU$=W="7R4\Q3NW1[1R#@<^M:_@KP[- M8^"!H^M6J@NT@DA9@P*L?4&MW6=9M]%M%FF62625Q'!!$,O*YZ*HK+.K>*4C M^T2>&X#%U,,=\#,!_P!\[2?;-%DBE3ITVEJ[*W??Y'&^&_A]JOAWXB0W:1B7 M2HC)LG+KD*R, "N_6KWB'6D\/Z)<:B\1F,>T) M$#@NS$ =?6BR)C2HQCH]$^;^O(Y/3?#VM>#_%4AT:W-WX?O&W2P>:H: ^HW M$9Q^HX/(!JK-X9\2>$-6%VVZ2RD8#:<]LD=,G!!SZ@UWL.J6\VB M)JV[%LUN+C/HNW=_*LD>+$3P_IVH3V4OVO40/LUC"V]Y">1@\<8P23P,T60W M2I)6O;JO+T_R.4FT3Q=XSUG3[C6K2VTNRL9?,55(9VY!/<\\#K@?6M7Q=X2U M.?6[;Q)XWIBM-]8\46\?VB?PW"\(Y:*WO0\RC MV!4!C[ UIIKMK<^'9-9LSYT"P/*!T)V@DJ?0Y&*+(2I4VFFW?>[T>APU_+\0 M_$EFVE/I-MID,PV3W'F#E3U ^8G!]@:[?PYH4'AO0[?3+=BXC!+R$8+L>2?\ M]L5D6GB+Q+>V$%]#X7A>":-94QJ2[BK#(X*=<'IFKZ^)[>;PM=ZW!!(?LJ2& M2WD^5T=/O(W7!XH5BJ:A%\[;;MU[?<;M%9=YKMKIVAQZI=;E61%*1)\SN[#A M%'M5#J\=K>"29!_NE0&/L#6O_ &FO_/G>_P#?@TK@JB9SOQ.N+.#P M->+=HS^:RI"%'23.0?;H?Y=Z\$T?4Y]&U>UU&V8B2"0.,'&X=P?8C(_&OJ*_ ML+75+&6RO85FMY5VNC=_\#[UX[=?!S4CKKPVMU$-,.62XD.64?W2HZGWZ?RJ M9)WNCS\;0J2FIP5SN;KXG>&X=%-_#=B68IE+4 B0M_=/I]>GIFO"M4UW4=7U M5]2N[EVN"VY2&(V>@7T K1\4^#=3\)S1B]\N2&8D131'(;';!Y!Y%8$43SS) M%$I:1V"JHZDGH*EMOO5?#^C7$5G97>N);W&M0PF(W*K\P4]B>Y]_KZG+2?4Z M:-"I.:E-6:Z]_P#@F]7+_$3/_"":GCKB/'_?Q*ZBLKQ)H[:]X?NM,2<0-/MQ M(5W!<,&Z9'I5O8].JG*$DNQE7:>.VM)1#+H0D*G:464-^&XD9^O%8M^UB?A) M;KIRRI;I+ FV;[X<3J'W>^[-= ^F^+)4*'Q!8Q!A@O'8'I;3\1=#$^-@M+@V^?^>OR M[L>^VNHK-UK18=:M8T>22">%Q+;W$1P\3CN/7W'>LLV'B^1/L[ZWIR1XP;F. MS;SC[X+;0:9JKPD]+W,J'3%U>X\AZSJE^LYE^V/F)"N/)4LS%1ST+,32L9^RDK>>_WW_P" Y$4C;U)]O+)'X5NF)(?B58PLH6"+2&6U4] PD ;'OMQ^%6YO" MTLQP.L\EK>VS^9;746-T3=#P> M""."#UHL"I22;[6MZ(U:X;3]HTGQP(/^/47%QLQT#^4-^/\ @5:;:?XNN$-M M-K6GPPD8,]O:,)B/;+%0??M6C'H-M:^&YM&LLQ1/ \0=OF.6!RS>IRUK7.2T[Q/K6D>%M&\SP_$+9X(((KI[Y0G*@*S@+E0??ITS5Z[T>;1_AWK MZW4J2WEU'<75PT8(3S'!)"Y[#@5T-MHL">&K?1;L+<0I:I;2$C $;G0KG4//9X7@BN63Y@A&%W#/) []\4K$>SG:SUT^XY[1)IO[Z&NEWJB6(1*A(X(('##T.1D53.C:G+HL5G)KDR7D$FZ*\B3!8#H)%) MP_7GUXIV*C!Q3BU=/^O^&,^XNO%?A^V>YNA9:S90*6D:-3!<;1U;'*G YP,5 M%_PM#PQ_S\S?]^35FYTCQ3J=K)87NKZ?%:2J4DEM;5A*ZG@CYF(7([XJ+_A6 M?A?_ )\G_P"_II:]"&JU_P!WMYG744451UGGOQ?C1O#-JS(I870 )'(^4UY; MX3BC?Q;I*LBD?:H^"/\ :%%%9RW/$Q?^\_ EX-101.DEF 4 dna-20220516_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 dna-20220516_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, State or Province Entity Address, State or Province Pre-commencement Tender Offer Pre-commencement Tender Offer Class of Stock [Domain] Class of Stock [Domain] City Area Code City Area Code Document And Entity Information [Line Items] Document And Entity Information [Line Items] Security Exchange Name Security Exchange Name Document Period End Date Document Period End Date Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share [Member] Warrant [Member] Class of Stock [Axis] Class of Stock [Axis] Entity Address, Address Line Two Entity Address, Address Line Two Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Entity Address, Address Line One Entity Address, Address Line One Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Entity Address, City or Town Entity Address, City or Town Trading Symbol Trading Symbol Local Phone Number Local Phone Number Common Class A [Member] Common Class A [Member] Title of 12(b) Security Title of 12(b) Security Entity Ex Transition Period Entity Ex Transition Period Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document And Entity Information [Table] Document And Entity Information [Table] Cover [Abstract] Cover [Abstract] Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Amendment Flag Amendment Flag EX-101.SCH 6 dna-20220516.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 7 dna-20220516_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 16, 2022
Document And Entity Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 16, 2022
Entity Registrant Name GINKGO BIOWORKS HOLDINGS, INC.
Entity Tax Identification Number 87-2652913
Entity Central Index Key 0001830214
Entity Incorporation, State or Country Code DE
Entity File Number 001-40097
Entity Emerging Growth Company true
Entity Ex Transition Period false
Local Phone Number 422-5362
Entity Address, State or Province MA
Entity Address, Address Line One 27 Drydock Avenue
Entity Address, Address Line Two 8th Floor
Entity Address, City or Town Boston
Entity Address, Postal Zip Code 02210
City Area Code 877
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share [Member]  
Document And Entity Information [Line Items]  
Trading Symbol DNA.WS
Title of 12(b) Security Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share
Security Exchange Name NYSE
Common Class A [Member]  
Document And Entity Information [Line Items]  
Trading Symbol DNA
Title of 12(b) Security Class A common stock, par value $0.0001 per share
Security Exchange Name NYSE
XML 9 dna-20220516_htm.xml IDEA: XBRL DOCUMENT 0001830214 us-gaap:CommonClassAMember 2022-05-16 2022-05-16 0001830214 us-gaap:WarrantMember 2022-05-16 2022-05-16 0001830214 2022-05-16 2022-05-16 0001830214 false 8-K 2022-05-16 GINKGO BIOWORKS HOLDINGS, INC. DE 001-40097 87-2652913 27 Drydock Avenue 8th Floor Boston MA 02210 877 422-5362 false false false false Class A common stock, par value $0.0001 per share DNA NYSE Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share DNA.WS NYSE true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 3 24 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports dna-20220516.htm dna-20220516.xsd dna-20220516_def.xml dna-20220516_lab.xml dna-20220516_pre.xml dna-ex99_1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dna-20220516.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "dna-20220516_def.xml" ] }, "inline": { "local": [ "dna-20220516.htm" ] }, "labelLink": { "local": [ "dna-20220516_lab.xml" ] }, "presentationLink": { "local": [ "dna-20220516_pre.xml" ] }, "schema": { "local": [ "dna-20220516.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 32, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 2, "nsprefix": "dna", "nsuri": "http://www.ginkgobioworks.com/20220516", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dna-20220516.htm", "contextRef": "C_a87111cf-5b9f-4a2a-94c2-5270bf57b6d7", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "dna-20220516.htm", "contextRef": "C_a87111cf-5b9f-4a2a-94c2-5270bf57b6d7", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dna_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.ginkgobioworks.com/20220516", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dna_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.ginkgobioworks.com/20220516", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.ginkgobioworks.com/20220516/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 16 0000950170-22-010067-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-010067-xbrl.zip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